NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes
FDA feedback supports NewcelX’s planned development strategy for NCEL-101 in combination with Tegoprubart FDA feedback supports NewcelX’s planned development strategy for NCEL-101 in combination with Tegoprubart
FDA feedback supports NewcelX’s planned development strategy for NCEL-101 in combination with Tegoprubart FDA feedback supports NewcelX’s planned development strategy for NCEL-101 in combination with Tegoprubart
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.